Recruiting
A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring - IM047-003
Oppdatert:
26 februar, 2024
|
ClinicalTrials.gov
Kjønn
Aldersgruppe
Sted(er)
Recruiting
Inclusion Criteria: - Diagnosis of Multiple sclerosis (MS) - Currently or recently pregnant - Reside in a country where ozanimod is prescribed for treatment of MS Exclusion Criteria: - Diagnostic prenatal test results known prior to first contact with the Registry Coordination Center (RCC) - Exposure to known teratogens and/or investigational medications during pregnancy Other protocol-defined inclusion/exclusion criteria apply
Vi anbefaler at du kontakter BMS for å rapportere bivirkninger.
Bivirkninger (uønskede hendelser) og andre rapporterbare hendelser er definert her
For å rapportere bivirkninger (uønskede hendelser) eller reklamere på et legemiddel: Medisinsk informasjon
MLTNO2000046